Short Interest in Glaukos Co. (NYSE:GKOS) Declines By 5.3%

Glaukos Co. (NYSE:GKOS) was the target of a significant drop in short interest during the month of November. As of November 30th, there was short interest totalling 2,660,000 shares, a drop of 5.3% from the November 15th total of 2,810,000 shares. Based on an average trading volume of 526,000 shares, the short-interest ratio is currently 5.1 days.

Insider Buying and Selling at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 2,275 shares of Glaukos stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total value of $316,156.75. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at $14,198,425.93. The trade was a 2.18 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gilbert H. Kliman sold 2,000 shares of the stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total transaction of $288,020.00. Following the sale, the director now directly owns 32,336 shares in the company, valued at $4,656,707.36. This represents a 5.82 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Glaukos

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Values First Advisors Inc. purchased a new position in shares of Glaukos during the third quarter worth about $25,000. Harvest Fund Management Co. Ltd boosted its position in shares of Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after purchasing an additional 860 shares during the period. Fifth Third Wealth Advisors LLC purchased a new position in Glaukos during the 2nd quarter worth approximately $187,000. KBC Group NV increased its position in Glaukos by 16.2% during the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after buying an additional 201 shares during the period. Finally, Brighton Jones LLC purchased a new stake in Glaukos in the second quarter valued at approximately $208,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on GKOS. JPMorgan Chase & Co. upped their target price on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. UBS Group assumed coverage on Glaukos in a research report on Friday, December 6th. They set a “buy” rating and a $182.00 price objective on the stock. BTIG Research lifted their target price on Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Stifel Nicolaus upped their price target on Glaukos from $145.00 to $153.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. Finally, Wells Fargo & Company lifted their price objective on Glaukos from $145.00 to $153.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $145.92.

Glaukos Trading Down 0.8 %

GKOS opened at $145.14 on Thursday. The business’s 50-day simple moving average is $136.95 and its 200-day simple moving average is $127.52. The company has a market cap of $8.00 billion, a P/E ratio of -48.06 and a beta of 1.03. Glaukos has a one year low of $74.75 and a one year high of $147.65. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.20. The company had revenue of $96.70 million for the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The firm’s revenue was up 23.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.50) earnings per share. As a group, equities research analysts expect that Glaukos will post -1.89 EPS for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.